Grasso's group is one of several involved in a large project designed to build biomimetic soft actuators capable of operating in a cluttered environment, maneuvering over and around objects, and then grabbing an object of interest and manipulating it.
Pursuing a wide variety of practical applications as well as the scientific knowledge they yield, other researchers in biomimetic robotics have produced mechanical mimics of lampreys, cockroaches, crickets, flies, snakes, dolphins, scorpions, and more.
As the field progresses, and the many groups working in biomimetic robotics increasingly collaborate and combine their specialized technologies, it seems likely that in the near future we will routinely see machines exploiting for human use many of the advantageous features nature has bestowed on animals over millions of years of evolution.
These investigations have yielded critical insights and have helped ML scientists and others progress toward the development of bio-inspired and bio-derived technologies--the principal research paths in the rapidly growing field of biomimetics.
The process of signal processing in biological systems, for example, is very complicated and well beyond the scope of current biomimetics.
The enormously complex, multistep biological processes associated with biomimetics often operate nonlinearly.
BioMimetic will be mailing a proxy statement/prospectus for its stockholders and each will be filing other documents regarding the proposed transaction with the SEC.
Except as required by law, BioMimetic undertakes no responsibility for updating the information contained in this press release beyond the published date, whether as a result of new information, future events or otherwise, and has no policy of doing so.
50 per share upon the achievement of $70 million in trailing twelve month sales for all products contributed by BioMimetic.
The transaction is expected to close in the first quarter of 2013 and is subject to customary closing conditions, including BioMimetic shareholder approval.
In 2005, BioMimetic received marketing approval from the FDA for its first product, GEM 21S[R], as a grafting material for bone and periodontal regeneration.
In November 2009, BioMimetic received approval from Health Canada to begin marketing Augment Bone Graft as an alternative to the use of autograft, the current gold standard in bone grafting, in foot and ankle fusion indications in Canada.